In support of this hypothesis, anti-NCAM1 autoantibodies disrupting the interaction of GDNF with NCAM1 could be detected in 5.4% of schizophrenia patients and injection of these antibodies precipitated schizophrenia-related symptoms in mice [21]. Here, NCAM1 is linked to schizophrenia.